-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ORM-5029 in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ORM-5029 in Gastric Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ORM-5029 in Gastric Cancer Drug Details: ORM-5029 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ORM-5029 in Bladder Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ORM-5029 in Bladder Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ORM-5029 in Bladder Cancer Drug Details: ORM-5029 is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ORM-5029 in Bile Duct Cancer (Cholangiocarcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ORM-5029 in Bile Duct Cancer (Cholangiocarcinoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ORM-5029 in Bile Duct Cancer (Cholangiocarcinoma) Drug Details: ORM-5029 is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ORM-5029 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ORM-5029 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ORM-5029 in Non-Small Cell Lung Cancer Drug Details: ORM-5029 is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ORM-5029 in Adenocarcinoma Of The Gastroesophageal Junction
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ORM-5029 in Adenocarcinoma Of The Gastroesophageal Junction report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ORM-5029 in Adenocarcinoma Of The Gastroesophageal Junction Drug Details:...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ORM-5029 in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ORM-5029 in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ORM-5029 in...
-
Thematic Analysis
NewRegulated mHealth Apps – Thematic Intelligence
Reasons to buy the ‘Regulated mHealth Apps’ thematic intelligence report: Gain insights on the key trends impacting the regulated mobile health apps theme, classified by technology, regulatory, and macroeconomic trends over the next 12 to 24 months. Understand how big the mHealth theme is, how fast it will grow, its timeline, and how the theme will develop. Analyze the core components of the mobile health value chain which includes mHealth devices, mHealth apps, mHealth app use, and experience. Find out...
-
Sector Analysis
Europe Fibercos and Towercos Market Dynamics and Opportunities
Europe Fibercos and Towercos Market Report Overview Fibercos and towercos in Europe are heading toward organic growth strategies for controlling debts and sustaining rollout targets. Furthermore, infrastructure companies are trying to reduce their carbon emissions by generating power to support their operations. Large consumer base and favorable regulatory environment in Europe have made the region the most viable choice for investments from international telecommunications players. Additionally, a surge in demand for high-speed connectivity in the European economies is encouraging telecom...
-
Thematic Analysis
Patient Empowerment – Thematic Intelligence
Reasons to buy the ‘Patient Empowerment’ thematic intelligence report: Assess patients’ health literacy. Understand interactions between patients and HCPs. Capture patients’ opinions on patient empowerment in healthcare. Gain a deeper understanding of shared decision-making. Evaluate patients’ access to disease and treatment information. Explore the role of pharmaceutical companies in empowering patients. How is our ‘Patient Empowerment’ report unique from other reports in the market? This report combines information obtained from secondary sources and primary research with patients suffering from chronic...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Risankizumab in Atopic Dermatitis (Atopic Eczema)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Risankizumab in Atopic Dermatitis (Atopic Eczema) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Risankizumab in Atopic Dermatitis (Atopic Eczema) Drug Details: Risankizumab (Skyrizi)...